drugset
drugset / Trial / NCT02738008

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

NCT02738008 ↗

Phase 2 Terminated 12 enrolled Arrowhead Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.

Timeline

Start
2016-03
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ARC-520 Unknown 2 mg/kg Intravenous
Background Cetirizine Other / unclassified 10 mg Oral
Background Chlorpheniramine Unknown 8 mg Oral
Background Diphenhydramine Unknown 50 mg Oral
Background Entecavir Small molecule 0.5 mg Oral
Background Entecavir Small molecule 1 mg Oral
Background Hydroxyzine Small molecule 50 mg Oral
Background Tenofovir Small molecule 300 mg Oral

Indications

hepatitis B virus infection